Pages
Products

miR-hsa-miR-26b-5p mimics

For research use only. Not intended for any clinical use.

Cat. No. :   MIMH0059

Inquire for Price

Product Information

Cat. No. MIMH0059
Species Human
Size 5 nmol
Sequence UUCAAGUAAUUCAGGAUAGGU
Inventory 5-7 days
Quick Inquiry

Case Study

Q & A

Customer Reviews

Myeloid cell-specific miR-26b-deficient mice show larger plaques compared to controls. Myeloid cell-specific miR-26b-deficient mice show larger plaques compared to controls.

MicroRNA-26b−/− augments atherosclerosis, while mimic-loaded nanoparticles reduce atherogenesis

Paper 2025
Cardiovascular Research | DOI
Background
MicroRNAs orchestrate complex inflammatory programs in atherosclerosis. This study reveals that miR-26b is a crucial atheroprotective factor by showing global and myeloid-specific MiR26b knockout in Apoe−/− mice significantly exacerbated aortic arch plaque formation and shifted lesions to advanced stages. Mechanistically, miR-26b loss drove pro-inflammatory macrophage activation and impaired collagen degradation through MMP3/MMP8, with Annexin A2 identified as a direct target. Reintroducing miR-26b via lipid nanoparticle-encapsulated mimics reversed these effects in vitro, reduced atherogenesis in vivo, and dampened human plaque inflammation, highlighting a promising RNA-based therapy.
Key Findings
Global Apoe−/−Mir26b−/− mice fed a Western diet developed 2.8-fold larger aortic arch plaques than Apoe−/− controls; plaques exhibited increased collagen, SMC, necrotic core, and advanced pathological score despite lower relative macrophage content. Myeloid-specific deletion similarly increased aortic arch plaque area 2.5-fold. Mir26b-deficient bone marrow-derived macrophages secreted more IL-6, TNF, CCL2, CCL5 and less IL-10, showed impaired efferocytosis and reduced collagenolytic activity, correlating with diminished Mmp3/Mmp8 expression. Pulldown and luciferase assays identified Annexin A2 as a direct miR-26b-5p target; AnxA2 knockdown abolished the effects of miR-26b mimics on MMPs and cytokines. Treatment of Apoe−/−Mir26b−/− mice with miR-26b mimic-loaded lipid nanoparticles reduced plaque area, and ex vivo culture of human atherosclerotic plaques with these nanoparticles lowered TNF and IL-1beta secretion. Thus, miR-26b prevents atherosclerosis by restraining inflammation and preserving matrix remodeling.
Contribution
Creative Biogene provided the synthetic 3'-biotinylated miR-26b-5p mimic and the microRNA pulldown assay protocol/kit used to isolate and identify Annexin A2 as a direct target of miR-26b.
Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction